Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR
Cytomegalovirus Infections
About this trial
This is an interventional diagnostic trial for Cytomegalovirus Infections focused on measuring cytomegalovirus viremia
Eligibility Criteria
Inclusion Criteria: Patients affiliated with Barnes-Jewish Hospital with CMV blood infection requiring antiviral therapy All patients will have a positive qualitative CMV PCR or viral culture before starting therapy Patients will receive treatment with ganciclovir at a dose and duration to be determined by the provider It is anticipated that most subjects will be organ transplant recipients but this is not a requirement of the study Exclusion Criteria: Critically ill patients Patients with profound leukopenia or abnormal renal function that make a change in the antiviral drug dosage likely during the duration of the study Anemia (HGB < 8 g/dl) that would contraindicate the extra blood draws required by this study Problems with vascular access that would interfere with obtaining blood samples required by this study Residence outside of the St. Louis metropolitan area during the period of ganciclovir therapy Patients who are unable to provide informed consent because of diminished capacity related to illness, dementia, or other reasons
Sites / Locations
- Infectious Diseases Division